FSD Pharm b Aktie [WKN DE: A2PTUT / ISIN: CA35954B2066]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu FSD Pharma Inc Registered Shs -B- Subordinate Vtg

26.08.23		FSD Pharma Rebuts Claims of GBB Drink Lab now acquired by Jupiter Wellness Inc. Trading under the symbol (NASDAQ: JUPW) (Businesswire)
17.07.23		Arbitration Panel Finds that Syneos Health (NASDAQ: SYNH) Failed to Use Commercially Reasonable Efforts in Conducting its Trial for FSD 201 (Businesswire)
10.07.23		FSD Pharma Retains Christian Attar Law and Team of Experts to Lead Preliminary Investigation of Possible Naked Short Selling and Manipulation in its stock (Businesswire)
04.07.23		FSD Pharma Appoints Zeeshan Saeed as Chief Executive Officer, Anthony Durkacz to Serve as Executive Co-Chairman of the Board of Directors (Businesswire)
30.06.23		FSD Pharma Inc. Announces Results of Annual General and Special Meeting of Shareholders (Businesswire)
21.06.23		DR. RAZA BOKHARI, FORMER EXECUTIVE CHAIRMAN AND CEO OF FSD PHARMA, FILES TWO ADDITIONAL CLAIMS AGAINST THE COMPANY SEEKING RELIEF AND MONETARY DAMAGES EXCEEDING $30.2 MILLION (PR Newswire)
20.06.23		FSD Pharma Announces Agreement to Grant Exclusive Rights to Revolutionary Recreational Alcohol Misuse Technology (Businesswire)
25.05.23		FSD Pharma Appoints Former Ontario Minister of Health Doctor Eric Hoskins to Board of Directors (Businesswire)
12.05.23		FSD Pharma Announces Receipt of Court Action and Update on Spin-Out and Distribution (Businesswire)
11.05.23		FSD Pharma Awarded $2.81 Million in Cost Awards From Dr. Raza Bokhari (Businesswire)
08.05.23		FSD Pharma to Present at Sidoti Virtual Investor Conference May 10-11 (Businesswire)
17.04.23		FSD Pharma Achieves Milestone in Completion of Dosing of Sentinel Subjects in First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis (Businesswire)
12.04.23		FSD Pharma Announces Plan to Spin-Out Subsidiary as Distribution to Shareholders; Shareholder Meeting Scheduled for June 29, 2023 (Businesswire)
30.03.23		FSD Pharma Adds Former Celsius Holdings CEO Gerry David to Board of Advisors (Businesswire)
22.03.23		FSD Pharma Announces Its Australian Entity Receives Approval to Proceed With Phase 1 Clinical Trial of Lucid-201, a Candidate for the Potential Treatment of Major Depressive Disorder (Businesswire)
28.02.23		Original "Shark” and Iconic Entrepreneur Kevin Harrington Joins FSD Pharma Advisory Board (Businesswire)
15.02.23		FSD Pharma Regains Compliance with NASDAQ Continued Listing Requirements (Businesswire)
14.02.23		FSD Pharma Launches A New Research and Development Program Targeting Unmet Medical Needs for Alcohol Misuse (Businesswire)
07.02.23		FSD Pharma Receives Regulatory Clearance for Its Proposed Phase-1 Clinical Trial of Lucid-21-302 (Lucid-MS), First-in-Class Multiple Sclerosis Drug Candidate (Businesswire)
30.01.23		Recruiting Underway in FSD Pharma’s Phase 2 Trial of FSD-PEA (FSD201) for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD) (Businesswire)
17.01.23		FSD Pharma submits its phase-1 Clinical Trial Application for Lucid-MS (Lucid-21-302) for first-in-human safety and tolerability investigation (Businesswire)
13.01.23		FSD Pharma Announces Share Repurchase Program (Businesswire)
28.11.22		FSD Pharma Announces Changes to the Board of Directors (Businesswire)
10.11.22		FSD Pharma Announces Arbitrator Dismisses Claims by Former CEO, Dr. Raza Bokhari (Businesswire)
29.09.22		FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency (Businesswire)
12.09.22		FSD Pharma Participating in H.C. Wainwright 24th Annual Global Investment Conference, On-Demand Presentation Available (Businesswire)
06.09.22		FDA and Health Canada Clear IND for FSD Pharma to Proceed with Phase 2 Trial of FSD201 for Nociplastic Pain Associated with Idiopathic Mast Cell Activation Syndrome (Businesswire)
13.07.22		FSD Pharma Subsidiary Lucid Psycheceuticals Files for Patent On Novel Formulations of Palmitoylethanolamide, Presents Preclinical Toxicology Results at an International Symposium (Businesswire)
27.06.22		FSD Pharma Inc. Announces Results of Annual General Meeting of Shareholders And Other Corporate Updates (Businesswire)
31.05.22		FSD Pharma Files Investigational New Drug Application ("IND”) with FDA and Health Canada for Phase-2 Trial of FSD-201 for an Inflammatory disorder and Provides Corporate Updates (Businesswire)
24.05.22		FSD Pharma Issues Circular, Adopts Incentive Plan and Grants PSUs (Businesswire)
10.05.22		FSD Pharma Closes CAD$16.4 Million Sale of Non-Core Assets (Businesswire)
06.05.22		FSD Pharma Announces Dismissal of Derivative Complaint (Businesswire)
21.04.22		FSD Pharma Appoints Julia Levy Award Recipient David Allan and Dr. John McGraw to Advisory Board (Businesswire)
08.04.22		FSD Pharma Announces Cancellation of Certain Shares Issued to Former Chief Executive Officer Dr. Raza Bokhari (Businesswire)
06.04.22		FSD Pharma Issues Corporate Updates (Businesswire)
15.03.22		FSD Pharma Announces Executive Informational Overview Report Produced by Crystal Research Associates LLC (Businesswire)
20.01.22		FSD Pharma Announces Launch of New Corporate Website (Businesswire)
18.01.22		FSD Pharma Congratulates Dr. Eleanor Fish on Being Named to the Order of Canada (Businesswire)
04.01.22		FSD Pharma to Present at the H.C. Wainwright Bioconnect Conference on January 10-13th (Businesswire)
17.05.21		FSD Pharma Inc. Announces Results of the Annual General and Special Meeting of Shareholders – Nominees of the Concerned Shareholders Elected to the Board of Directors (Businesswire)
30.11.20		Pre-market Movers In Healthcare Sector: ORMP, VSTM, MRNA, COCP, SYBX... (RTTNews)
24.11.20		Pre-market Movers In Healthcare Sector: HUGE, ADXS, DBVT, AEZS, BNTX… (RTTNews)
29.09.20		Pre-market Movers In Healthcare Sector: TNXP, SRNE, GNFT, INO, HUGE… (RTTNews)
28.09.20		Pre-market Movers In Healthcare Sector: GNFT, HUGE, ACOR, AQST... (RTTNews)
31.08.20		Pre-market Movers In Healthcare Sector: AIMT, HUGE, AMRN, EVFM, LPCN... (RTTNews)
31.07.20		FSD Pharma To Surrender Marijuana Licenses To Health Canada (RTTNews)
28.12.19		Cannabis-Branche im Fokus: Kanadisches Biotech-Unternehmen geht an die Nasdaq (finanzen.at) Am Cannabis-Markt kriselt es aktuell etwas. Während die Cannabis-Blase geplatzt zu sein scheint, plant ein Unternehmen aktuell die Notierung seiner Aktien an der US-Börse Nasdaq.» mehr

Newssuche

FSD Pharm b Peer Group Nachrichten

28.12.19

Cannabis-Branche im Fokus: Kanadisches Biotech-Unternehmen geht an die Nasdaq

Meistgelesene Nachrichten

Pierer Mobility-Aktie knickt ein: KTM wird Produktionsstopp womöglich verlängern

2024: Das sind die Tops und Flops der DAX-Aktien

Banque Syz prognostiziert Überraschungen für 2025: Musk-Meloni-Hochzeit und das Ende der Musk-Trump-Verbindung

ATX-Wert voestalpine-Aktie: So viel Verlust hätte ein Investment in voestalpine von vor 5 Jahren bedeutet

Steinmeier setzt Neuwahlen für 23. Februar an

ATX beendet letzten Handelstag des Jahres im Plus -- DAX letztlich mit Verlusten

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	02.01.2025 04:53
Kaufwert:	EUR
	Hinzufügen Speichern